Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review

Gabriele Sani; Tommaso Callovini; Ottavia Ferrara; Daniele Segatori; Stella Margoni; Alessio Simonetti; Francesco Lisci; Giuseppe Marano; Alessia Fischetti; Georgios Kotzalidis; Federica Di Segni; Federica Fiaschè; Delfina Janiri; Lorenzo Moccia; Giovanni Manfredi; Alessandro Alcibiade; Caterina Brisi; Flavia Grisoni; Gianmarco Stella; Evelina Bernardi; Andrea Brugnami; Michele Ciliberto; Maria Spera; Romina Caso; Sara Rossi; Gianluca Boggio; Giulia Mastroeni; Francesca Abate; Eliana Conte; Anna Quintano; Lavinia De Chiara; Laura Monti; Giovanni Camardese; Lucio Rinaldi; Alexia Koukopoulos; Daniela Chieffo; Gloria Angeletti; Marianna Mazza

doi:10.2174/1570159X22666240516151449

Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review

作者: Sani G.¹, Callovini T.², Ferrara O.³, Segatori D.⁴, Margoni S.⁴, Simonetti A.⁵, Lisci F.⁴, Marano G.⁵, Fischetti A.⁴, Kotzalidis G.⁵, Di Segni F.⁶, Fiaschè F.⁷, Janiri D.⁵, Moccia L.⁸, Manfredi G.⁹, Alcibiade A.⁶, Brisi C.⁴, Grisoni F.⁴, Stella G.³, Bernardi E.³, Brugnami A.³, Ciliberto M.⁴, Spera M.¹⁰, Caso R.¹⁰, Rossi S.³, Boggio G.⁴, Mastroeni G.³, Abate F.⁴, Conte E.¹⁰, Quintano A.⁴, De Chiara L.¹¹, Monti L.¹², Camardese G.⁸, Rinaldi L.¹, Koukopoulos A.¹³, Chieffo D.¹², Angeletti G.¹⁴, Mazza M.⁸
隶属关系:
1. Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS,
2. Department of Medicine and Surgery,, University of Milano-Bicocca
3. Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore
4. Department of Neuroscience, Section of Psychiatry,, Università Cattolica del Sacro Cuore
5. Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
6. Psychiatry Residency Training Programme, Faculty of Medicine and Psychology, Sapienza University of Rome
7. ASL RM1, Presidio Ospedaliero San Filippo Neri, Servizio Psichiatrico di Diagnosi e Cura
8. Department of Psychiatry,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
9. UOC Psichiatria, Day Hospital, Sant'Andrea Teaching Hospital, Sapienza University of Rome
10. Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore,
11. , Struttura Residenziale Psichiatrica Samadi S.p.A.
12. UOS Clinical Psychology, Clinical Government, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
13. Azienda Ospedaliera Universitaria Policlinico Umberto I, Viale dellUniversità 30
14. Sapienza University of Rome, Sant'Andrea Hospital, Sapienza University of Rome
期: 卷 22, 编号 14 (2024)
页面: 2402-2421
栏目: Neurology
URL: https://rjpbr.com/1570-159X/article/view/644570
DOI: https://doi.org/10.2174/1570159X22666240516151449
ID: 644570

如何引用文章

全文:

详细
作者简介
参考
补充文件
统计

详细

:There is much debate about continuing antipsychotic medication in patients who need it when they become pregnant because benefits must be weighed against potential teratogenic and malformation effects related to antipsychotics themselves. To address this, we conducted a systematic review on the PubMed, PsycINFO and CINHAL databases and the ClinicalTrials.gov register using the following strategy: (toxicity OR teratogenicity OR malformation* OR \"birth defect*\" OR \"congenital abnormality\" OR \"congenital abnormalities\" OR \"brain changes\" OR \"behavioral abnormalities\" OR \"behavioral abnormalities\") AND antipsychotic* AND (pregnancy OR pregnant OR lactation OR delivery OR prenatal OR perinatal OR post-natal OR puerperium) on September 27, 2023. We found 38 studies to be eligible. The oldest was published in 1976, while most articles were recent. Most studies concluded that the antipsychotics, especially the second-generation antipsychotics, were devoid of teratogenic potential, while few studies were inconclusive and recommended replication. Most authoritative articles were from the Boston area, where large databases were implemented to study the malformation potential of psychiatric drugs. Other reliable databases are from Northern European registers. Overall conclusions are that antipsychotics are no more related to malformations than the disorders themselves; most studies recommend that there are no reasons to discontinue antipsychotic medications in pregnancy

关键词

Pregnancy, malformations, major, teratogenicity, lactation, antipsychotic drugs, second generation antipsychotics.

参考

Davies, C.; Segre, G.; Estradé, A.; Radua, J.; De Micheli, A.; Provenzani, U.; Oliver, D.; Salazar de Pablo, G.; Ramella-Cravaro, V.; Besozzi, M.; Dazzan, P.; Miele, M.; Caputo, G.; Spallarossa, C.; Crossland, G.; Ilyas, A.; Spada, G.; Politi, P.; Murray, R.M.; McGuire, P.; Fusar-Poli, P. Prenatal and perinatal risk and protective factors for psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 2020, 7(5), 399-410. doi: 10.1016/S2215-0366(20)30057-2 PMID: 32220288
Howard, L.M.; Khalifeh, H. Perinatal mental health: A review of progress and challenges. World Psychiatry, 2020, 19(3), 313-327. doi: 10.1002/wps.20769 PMID: 32931106
Orsolini, L.; Sceusa, F.; Pompili, S.; Mauro, A.; Salvi, V.; Volpe, U. Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: Focus on second-generation long acting injectable antipsychotics. Expert Opin. Drug Saf., 2021, 20(10), 1207-1224. doi: 10.1080/14740338.2021.1928634 PMID: 33966552
Wesseloo, R.; Kamperman, A.M.; Bergink, V.; Pop, V.J.M. Thyroid peroxidase antibodies during early gestation and the subsequent risk of first-onset postpartum depression: A prospective cohort study. J. Affect. Disord., 2018, 225, 399-403. doi: 10.1016/j.jad.2017.08.058 PMID: 28850854
Valdimarsdóttir, U.; Hultman, C.M.; Harlow, B.; Cnattingius, S.; Sparén, P. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: A population-based study. PLoS Med., 2009, 6(2), e1000013. doi: 10.1371/journal.pmed.1000013 PMID: 19209952
OHara, M.W.; Wisner, K.L. Perinatal mental illness: Definition, description and aetiology. Best Pract. Res. Clin. Obstet. Gynaecol., 2014, 28(1), 3-12. doi: 10.1016/j.bpobgyn.2013.09.002 PMID: 24140480
Cuomo, A.; Goracci, A.; Fagiolini, A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J. Affect. Disord., 2018, 228, 229-237. doi: 10.1016/j.jad.2017.12.021 PMID: 29275156
Winans, E.A. Antipsychotics and Breastfeeding. J. Hum. Lact., 2001, 17(4), 344-347. doi: 10.1177/089033440101700408 PMID: 11847903
Conejo-Galindo, J.; Sanz-Giancola, A.; Álvarez-Mon, M.Á.; Ortega, M.Á.; Gutiérrez-Rojas, L.; Lahera, G. Postpartum relapse in patients with bipolar disorder. J. Clin. Med., 2022, 11(14), 3979. doi: 10.3390/jcm11143979 PMID: 35887743
Edinoff, A.N.; Sathivadivel, N.; McNeil, S.E.; Ly, A.I.; Kweon, J.; Kelkar, N.; Cornett, E.M.; Kaye, A.M.; Kaye, A.D. Antipsychotic use in pregnancy: Patient mental health challenges, teratogenicity, pregnancy complications, and postnatal risks. Neurol. Int., 2022, 14(1), 62-74. doi: 10.3390/neurolint14010005 PMID: 35076595
Munk-Olsen, T.; Laursen, T.M.; Mendelson, T.; Pedersen, C.B.; Mors, O.; Mortensen, P.B. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch. Gen. Psychiatry, 2009, 66(2), 189-195. doi: 10.1001/archgenpsychiatry.2008.528 PMID: 19188541
Sprague, J.; Wisner, K.L.; Bogen, D.L. Pharmacotherapy for depression and bipolar disorder during lactation: A framework to aid decision making. Semin. Perinatol., 2020, 44(3), 151224. doi: 10.1016/j.semperi.2020.151224 PMID: 32199600
McAllister-Williams, R.H.; Baldwin, D.S.; Cantwell, R.; Easter, A.; Gilvarry, E.; Glover, V.; Green, L.; Gregoire, A.; Howard, L.M.; Jones, I.; Khalifeh, H.; Lingford-Hughes, A.; McDonald, E.; Micali, N.; Pariante, C.M.; Peters, L.; Roberts, A.; Smith, N.C.; Taylor, D.; Wieck, A.; Yates, L.M.; Young, A.H. British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J. Psychopharmacol., 2017, 31(5), 519-552. doi: 10.1177/0269881117699361 PMID: 28440103
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71. doi: 10.1136/bmj.n71 PMID: 33782057
ROBINS-E Development Group. Higgins, J.; Morgan, R.; Rooney, A.; Taylor, K.; Thayer, K.; Silva, R .; Lemeris, C.; Akl, A.; Arroyave, W.; Bateson, T.; Berkman, N.; Demers, P.; Forastiere, F.; Glenn, B.; Hróbjartsson, A.; Kirrane, E.; LaKind, J.; Luben, T.; Lunn, R.; McAleenan, A.; McGuinness, L.; Meerpohl, J.; Mehta, S.; Nachman, R.; Obbagy, J.; O'Connor, A.; Radke, E.; Savović, J.; Schubauer-Berigan, M.; Schwingl, P.; Schunemann, H.; Shea, B.; Steenland, K.; Stewart, T.; Straif, K.; Tilling, K.; Verbeek, V.; Vermeulen, R.; Viswanathan, M.; Zahm, S.; Sterne, J. Risk Of Bias In Non-randomized Studies of Exposure (ROBINS-E). Launch version, 20 June 2023. Available from: https://www.riskofbias.info/welcome/robins-e-tool (assessed on August 25, 2023.)
Rieder, R.O.; Rosenthal, D.; Wender, P.; Blumenthal, H. The offspring of schizophrenics. Fetal and neonatal deaths. Arch. Gen. Psychiatry, 1975, 32(2), 200-211. doi: 10.1001/archpsyc.1975.01760200064006 PMID: 234727
Milkovich, L.; van den Berg, B.J. An evaluation of the teratogenicity of certain antinauseant drugs. Am. J. Obstet. Gynecol., 1976, 125(2), 244-248. doi: 10.1016/0002-9378(76)90601-3 PMID: 773181
McKeigue, P.M.; Lamm, S.H.; Linn, S.; Kutcher, J.S. Bendectin and birth defects: I. A meta‐analysis of the epidemiologic studies. Teratology, 1994, 50(1), 27-37. doi: 10.1002/tera.1420500105 PMID: 7974252
Slone, D.; Siskind, V.; Heinonen, O.P.; Monson, R.R.; Kaufman, D.W.; Shapiro, S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am. J. Obstet. Gynecol., 1977, 128(5), 486-488. doi: 10.1016/0002-9378(77)90029-1 PMID: 879206
Godet, P.F.; Marie-Cardine, M. Neuroleptiques, schizophrénie et grossesse. Etude épidémiologique et tératologique. Encephale, 1991, 17(6), 543-547. PMID: 1687216
Sharma, J.B.; Sharma, S. Role of thioridazine in unexplained infertility. Int. J. Gynaecol. Obstet., 1992, 37(1), 37-41. doi: 10.1016/0020-7292(92)90975-O PMID: 1346599
Goldstein, D.J.; Corbin, L.A.; Fung, M.C. Olanzapine-exposed pregnancies and lactation: Early experience. J. Clin. Psychopharmacol., 2000, 20(4), 399-403. doi: 10.1097/00004714-200008000-00002 PMID: 10917399
Diav-Citrin, O.; Shechtman, S.; Ornoy, S.; Arnon, J.; Schaefer, C.; Garbis, H.; Clementi, M.; Ornoy, A. Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective, controlled study. J. Clin. Psychiatry, 2005, 66(3), 317-322. doi: 10.4088/JCP.v66n0307 PMID: 15766297
McKenna, K.; Koren, G.; Tetelbaum, M.; Wilton, L.; Shakir, S.; Diav-Citrin, O.; Levinson, A.; Zipursky, R.B.; Einarson, A. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J. Clin. Psychiatry, 2005, 66(4), 444-449. doi: 10.4088/JCP.v66n0406 PMID: 15816786
Reis, M.; Källén, B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J. Clin. Psychopharmacol., 2008, 28(3), 279-288. doi: 10.1097/JCP.0b013e318172b8d5 PMID: 18480684
Babu, G.N.; Desai, G.; Tippeswamy, H.; Chandra, P.S. Birth weight and use of olanzapine in pregnancy: A prospective comparative study. J. Clin. Psychopharmacol., 2010, 30(3), 331-332. doi: 10.1097/JCP.0b013e3181db8734 PMID: 20473073
Gilad, O.; Merlob, P.; Stahl, B.; Klinger, G. Outcome of infants exposed to olanzapine during breastfeeding. Breastfeed. Med., 2011, 6(2), 55-58. doi: 10.1089/bfm.2010.0027 PMID: 21034242
Habermann, F.; Fritzsche, J.; Fuhlbrück, F.; Wacker, E.; Allignol, A.; Weber-Schoendorfer, C.; Meister, R.; Schaefer, C. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study. J. Clin. Psychopharmacol., 2013, 33(4), 453-462. doi: 10.1097/JCP.0b013e318295fe12 PMID: 23764684
Sadowski, A.; Todorow, M.; Yazdani Brojeni, P.; Koren, G.; Nulman, I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: A cohort study. BMJ Open, 2013, 3(7), e003062. doi: 10.1136/bmjopen-2013-003062 PMID: 23852139
Bellet, F.; Beyens, M.N.; Bernard, N.; Beghin, D.; Elefant, E.; Vial, T. Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study. Pharmacoepidemiol. Drug Saf., 2015, 24(4), 368-380. doi: 10.1002/pds.3749 PMID: 25683615
Cohen, L.S.; Viguera, A.C.; McInerney, K.A.; Freeman, M.P.; Sosinsky, A.Z.; Moustafa, D.; Marfurt, S.P.; Kwiatkowski, M.A.; Murphy, S.K.; Farrell, A.M.; Chitayat, D.; Hernández-Díaz, S. Reproductive safety of second-generation antipsychotics: Current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Am. J. Psychiatry, 2016, 173(3), 263-270. doi: 10.1176/appi.ajp.2015.15040506 PMID: 26441156
Montastruc, F.; Salvo, F.; Arnaud, M.; Bégaud, B.; Pariente, A. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: A disproportionality analysis using data from Vigibase. Drug Saf., 2016, 39(7), 689-696. doi: 10.1007/s40264-016-0413-1 PMID: 26961536
Petersen, I.; McCrea, R.L.; Sammon, C.J.; Osborn, D.P.J.; Evans, S.J.; Cowen, P.J.; Freemantle, N.; Nazareth, I. Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records. Health Technol. Assess., 2016, 20(23), 1-176. doi: 10.3310/hta20230 PMID: 27029490
Petersen, I.; Sammon, C.J.; McCrea, R.L.; Osborn, D.P.J.; Evans, S.J.; Cowen, P.J.; Nazareth, I. Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records. Schizophr. Res., 2016, 176(2-3), 349-356. doi: 10.1016/j.schres.2016.07.023 PMID: 27484686
Huybrechts, K.F.; Hernández-Díaz, S.; Patorno, E.; Desai, R.J.; Mogun, H.; Dejene, S.Z.; Cohen, J.M.; Panchaud, A.; Cohen, L.; Bateman, B.T. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry, 2016, 73(9), 938-946. doi: 10.1001/jamapsychiatry.2016.1520 PMID: 27540849
Hatters, F.S.; Moller-Olsen, C.; Prakash, C.; North, A. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int. J. Psychiatry Med., 2016, 51(6), 521-533. doi: 10.1177/0091217417696739 PMID: 28629296
Shin, Y.J.; Choi, J.S.; Ahn, H.K.; Ryu, H.M.; Kim, M.Y.; Han, J.Y. Pregnancy outcomes in women reporting ingestion of levosulpiride in early pregnancy. J. Obstet. Gynaecol., 2017, 37(8), 992-995. doi: 10.1080/01443615.2017.1312307 PMID: 28631490
Onken, M.; Mick, I.; Schaefer, C. Paliperidone and pregnancy: An evaluation of the German Embryotox database. Arch. Women Ment. Health, 2018, 21(6), 657-662. doi: 10.1007/s00737-018-0828-z PMID: 29569043
Galbally, M.; Frayne, J.; Watson, S.J.; Snellen, M. Aripiprazole and pregnancy: A retrospective, multicentre study. J. Affect. Disord., 2018, 238, 593-596. doi: 10.1016/j.jad.2018.06.004 PMID: 29957476
Cohen, L.S.; Góez-Mogollón, L.; Sosinsky, A.Z.; Savella, G.M.; Viguera, A.C.; Chitayat, D.; Hernández-Díaz, S.; Freeman, M.P. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am. J. Psychiatry, 2018, 175(12), 1225-1231. doi: 10.1176/appi.ajp.2018.18010098 PMID: 30111186
Anderson, K.N.; Ailes, E.C.; Lind, J.N.; Broussard, C.S.; Bitsko, R.H.; Friedman, J.M.; Bobo, W.V.; Reefhuis, J.; Tinker, S.C. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 19972011. Schizophr. Res., 2020, 215, 81-88. doi: 10.1016/j.schres.2019.11.019 PMID: 31761471
Ellfolk, M.; Leinonen, M.K.; Gissler, M.; Lahesmaa-Korpinen, A.M.; Saastamoinen, L.; Nurminen, M.L.; Malm, H. Second-generation antipsychotics and pregnancy complications. Eur. J. Clin. Pharmacol., 2020, 76(1), 107-115. doi: 10.1007/s00228-019-02769-z PMID: 31680189
Ellfolk, M.; Leinonen, M.K.; Gissler, M.; Kiuru-Kuhlefelt, S.; Saastamoinen, L.; Malm, H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur. J. Clin. Pharmacol., 2021, 77(11), 1737-1745. doi: 10.1007/s00228-021-03169-y PMID: 34100993
Freeman, M.P.; Viguera, A.C.; Góez-Mogollón, L.; Young, A.V.; Caplin, P.S.; McElheny, S.A.; Church, T.R.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Reproductive safety of aripiprazole: Data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. Arch. Women Ment. Health, 2021, 24(4), 659-667. doi: 10.1007/s00737-021-01115-6 PMID: 33710399
Viguera, A.C.; Freeman, M.P.; Góez-Mogollón, L.; Sosinsky, A.Z.; McElheny, S.A.; Church, T.R.; Young, A.V.; Caplin, P.S.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Reproductive safety of second-generation antipsychotics: updated data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. J. Clin. Psychiatry, , 2021, 82(4), 20m13745. doi: 10.4088/JCP.20m13745
Nguyen, T.; Frayne, J.; Watson, S.; Lebedevs, T.; Teoh, S.; Galbally, M. Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital. Psychiatry Res., 2022, 313, 114614. doi: 10.1016/j.psychres.2022.114614 PMID: 35576628
Yakuwa, N.; Takahashi, K.; Anzai, T.; Ito, N.; Goto, M.; Koinuma, S.; Uno, C.; Suzuki, T.; Watanabe, O.; Yamatani, A.; Murashima, A. Pregnancy outcomes with exposure to second-generation antipsychotics during the first trimester. Clin. Psychiatry, 2022, 83(4), 21m14081. doi: 10.4088/JCP.21m14081
Hálfdánarson, Ó.; Cohen, J.M.; Karlstad, Ø.; Cesta, C.E.; Bjørk, M.H.; Håberg, S.E.; Einarsdóttir, K.; Furu, K.; Gissler, M.; Hjellvik, V.; Kieler, H.; Leinonen, M.K.; Nørgaard, M.; Öztürk Esen, B.; Ulrichsen, S.P.; Reutfors, J.; Zoega, H. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: A Nordic cohort study. Evid. Based Ment. Health, 2022, 25(2), 54-62. doi: 10.1136/ebmental-2021-300311 PMID: 34810174
Straub, L.; Hernández-Díaz, S.; Bateman, B.T.; Wisner, K.L.; Gray, K.J.; Pennell, P.B.; Lester, B.; McDougle, C.J.; Suarez, E.A.; Zhu, Y.; Zakoul, H.; Mogun, H.; Huybrechts, K.F. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: A National Birth Cohort Study. JAMA Intern. Med., 2022, 182(5), 522-533. doi: 10.1001/jamainternmed.2022.0375 PMID: 35343998
Huybrechts, K.F.; Straub, L.; Karlsson, P.; Pazzagli, L.; Furu, K.; Gissler, M.; Hernandez-Diaz, S.; Nørgaard, M.; Zoega, H.; Bateman, B.T.; Cesta, C.E.; Cohen, J.M.; Leinonen, M.K.; Reutfors, J.; Selmer, R.M.; Suarez, E.A.; Ulrichsen, S.P.; Kieler, H. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry, 2023, 80(2), 156-166. doi: 10.1001/jamapsychiatry.2022.4109 PMID: 36477338
Cohen, L.S.; Church, T.R.; Freeman, M.P.; Gaccione, P.; Caplin, P.S.; Kobylski, L.A.; Arakelian, M.; Rossa, E.T.; Chitayat, D.; Hernández-Díaz, S.; Viguera, A.C. Reproductive safety of lurasidone and quetiapine: Update from the national pregnancy registry for psychiatric medications. J. Womens Health , 2023, 32(4), 452-462. doi: 10.1089/jwh.2022.0310 PMID: 36716275
Viguera, A.C.; Freeman, M.P.; Kobylski, L.A.; Rossa, E.T.; Gaccione, P.; Chitayat, D.; Hernández-Díaz, S.; Cohen, L.S. Risk of major malformations following first-trimester exposure to olanzapine: Preliminary data from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. J. Clin. Psychopharmacol., 2023, 43(2), 106-112. doi: 10.1097/JCP.0000000000001665 PMID: 36825887
Liu, X.; Kolding, L.; Momen, N.; Gasse, C.; Pedersen, L.H. Maternal antipsychotic use during pregnancy and congenital malformations. Am. J. Obstet. Gynecol. MFM, 2023, 5(6), 100950. doi: 10.1016/j.ajogmf.2023.100950 PMID: 37015311
Schrijver, L.; Robakis, T.K.; Kamperman, A.M.; Bijma, H.; Honig, A.; van Kamp, I.L.; Hoogendijk, W.J.G.; Bergink, V.; Poels, E.M.P. Neurodevelopment in school‐aged children after intrauterine exposure to antipsychotics. Acta Psychiatr. Scand., 2023, 147(1), 43-53. doi: 10.1111/acps.13517 PMID: 36333825
Idänpään-Heikkilä, J.; Alhava, E.; Olkinuora, M.; Palva, I. Letter: Clozapine and agranulocytosis. Lancet, 1975, 306(7935), 611. doi: 10.1016/S0140-6736(75)90206-8 PMID: 51442
Meltzer, H.Y.; Bastani, B.; Ramirez, L.; Matsubara, S. Clozapine: New research on efficacy and mechanism of action. Eur. Arch. Psychiatry Neurol. Sci., 1989, 238(5-6), 332-339. doi: 10.1007/BF00449814 PMID: 2569975
Perrault, G.; Schoemaker, H.; Scatton, B. Place de lamisulpride dans la classe des neuroleptiques atypiques. Encephale, 1996, 22(Spec No 2), 3-8. PMID: 8767034
Citrome, L.; Holt, R.I.G.; Walker, D.J.; Hoffmann, V.P. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin. Drug Investig., 2011, 31(7), 455-482. doi: 10.2165/11589060-000000000-00000 PMID: 21495734
Lambert, T.J.R. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evid. Based Ment. Health, 2009, 12(2), 50. doi: 10.1136/ebmh.12.2.50 PMID: 19395609
Tyrrell, J.; Richmond, R.C.; Palmer, T.M.; Feenstra, B.; Rangarajan, J.; Metrustry, S.; Cavadino, A.; Paternoster, L.; Armstrong, L.L.; De Silva, N.M.G.; Wood, A.R.; Horikoshi, M.; Geller, F.; Myhre, R.; Bradfield, J.P.; Kreiner-Møller, E.; Huikari, V.; Painter, J.N.; Hottenga, J.J.; Allard, C.; Berry, D.J.; Bouchard, L.; Das, S.; Evans, D.M.; Hakonarson, H.; Hayes, M.G.; Heikkinen, J.; Hofman, A.; Knight, B.; Lind, P.A.; McCarthy, M.I.; McMahon, G.; Medland, S.E.; Melbye, M.; Morris, A.P.; Nodzenski, M.; Reichetzeder, C.; Ring, S.M.; Sebert, S.; Sengpiel, V.; Sørensen, T.I.A.; Willemsen, G.; de Geus, E.J.C.; Martin, N.G.; Spector, T.D.; Power, C.; Järvelin, M.R.; Bisgaard, H.; Grant, S.F.A.; Nohr, E.A.; Jaddoe, V.W.; Jacobsson, B.; Murray, J.C.; Hocher, B.; Hattersley, A.T.; Scholtens, D.M.; Davey Smith, G.; Hivert, M.F.; Felix, J.F.; Hyppönen, E.; Lowe, W.L., Jr; Frayling, T.M.; Lawlor, D.A.; Freathy, R.M. Genetic evidence for causal relationships between maternal obesity-related traits and birth weight. JAMA, 2016, 315(11), 1129-1140. doi: 10.1001/jama.2016.1975 PMID: 26978208
Schmidt, M.; Schmidt, S.A.J.; Sandegaard, J.L.; Ehrenstein, V.; Pedersen, L.; Sørensen, H.T. The danish national patient registry: A review of content, data quality, and research potential. Clin. Epidemiol., 2015, 7, 449-490. doi: 10.2147/CLEP.S91125 PMID: 26604824
Lynge, E.; Sandegaard, J.L.; Rebolj, M. The danish national patient register. Scand. J. Public Health,, 2011, 39(7_suppl)(Suppl.), 30-33. doi: 10.1177/1403494811401482 PMID: 21775347
Cohen, L.S.; Viguera, A.C.; McInerney, K.A.; Kwiatkowski, M.A.; Murphy, S.K.; Lemon, E.L.; Hernández-Díaz, S. Establishment of the national pregnancy registry for atypical antipsychotics. J. Clin. Psychiatry, 2015, 76(7), 986-989. doi: 10.4088/JCP.14br09418 PMID: 25939066
Vari, I.S.; Balkau, B.; Kettaneh, A.; André, P.; Tichet, J.; Fumeron, F.; Caces, E.; Marre, M.; Grandchamp, B.; Ducimetière, P. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care, 2007, 30(7), 1795-1801. doi: 10.2337/dc06-2312 PMID: 17416791
Musenga, A.; Saracino, M.; Sani, G.; Raggi, M. Antipsychotic and antiepileptic drugs in bipolar disorder: The importance of therapeutic drug monitoring. Curr. Med. Chem., 2009, 16(12), 1463-1481. doi: 10.2174/092986709787909604 PMID: 19355900
Wang, Z.; Brauer, R.; Man, K.K.C.; Alfageh, B.; Mongkhon, P.; Wong, I.C.K. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis. Br. J. Clin. Pharmacol., 2021, 87(11), 4101-4123. doi: 10.1111/bcp.14839 PMID: 33772841
Hillemacher, T.; Simen, S.; Rehme, M.K.; Frieling, H. Antipsychotics during pregnancy: A systematic review. Nervenarzt, 2021, 92(5), 494-500. doi: 10.1007/s00115-020-01006-8
Gentile, S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull., 2010, 36(3), 518-544. doi: 10.1093/schbul/sbn107 PMID: 18787227
Gentile, S.; Fusco, M.L. Schizophrenia and motherhood. Psychiatry Clin. Neurosci., 2019, 73(7), 376-385. doi: 10.1111/pcn.12856 PMID: 31026107
Oyebode, F.; Rastogi, A.; Berrisford, G.; Coccia, F. Psychotropics in pregnancy: Safety and other considerations. Pharmacol. Ther., 2012, 135(1), 71-77. doi: 10.1016/j.pharmthera.2012.03.008 PMID: 22483705
Coughlin, C.G.; Blackwell, K.A.; Bartley, C.; Hay, M.; Yonkers, K.A.; Bloch, M.H. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet. Gynecol., 2015, 125(5), 1224-1235. doi: 10.1097/AOG.0000000000000759 PMID: 25932852
Centorrino, F.; Fogarty, K.V.; Sani, G.; Salvatore, P.; Cincotta, S.L.; Hennen, J.; Guzzetta, F.; Talamo, A.; Saadeh, M.G.; Baldessarini, R.J. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum. Psychopharmacol., 2005, 20(7), 485-492. doi: 10.1002/hup.719 PMID: 16116665
Centorrino, F.; Fogarty, K.V.; Sani, G.; Salvatore, P.; Cimbolli, P.; Baldessarini, R.J. Antipsychotic drug use: McLean Hospital, 2002. Hum. Psychopharmacol., 2005, 20(5), 355-358. doi: 10.1002/hup.700 PMID: 15957153

补充文件

附件文件

动作

1. JATS XML

下载

用户名
密码
记住我

忘记您的密码?	注册

用户名
密码
记住我

忘记您的密码?	注册

Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review

全文:

详细

关键词

作者简介

参考

补充文件